 Texas Heart Institute was founded by Denton Cooley, who was one of the pioneers in cardiac surgery and development of the artificial heart. Here at the Texas Heart Institute's clinical arrhythmia research and innovations department, we create ideas, we innovate, and we take those ideas and we develop those ideas from conception through preclinical testing. The goal is to improve our patient's outcomes, specifically those patients with heart rhythm disorders. Since the development of the institution here at the Texas Heart Institute, we've been very involved in innovation and development of new and exciting technologies, from heart transplantation to development of the mechanical circulatory devices, which include LVADs and now the smaller implantable pumps like Impella. We've also been very deeply involved in the development of new electrophysiologic technology such as the Lariat and uniquely this new horizon of developing a pacemaker from nanotechnology. The Lariat device, the device which is closing the left atrial appendage, left atrial appendage is space where the blood can hang around and blood clot can be formed in patients who have atrial fibrillation. The device was invented at Texas Heart Institute and the advantage of the Lariat is that it's closing that space but it also allows electrical isolation of the appendage, which we are right now studying to see the benefit in treatment of persistent atrial fibrillation. We are hoping to see an increase in success of the procedure. However, it is a study that would look at 400 to 600 patients. Right now we have included about 330 patients and the first interim analysis would come after completion of 400 patients. The collaborations with industry are critical because they provide a focus that enables development of our fellow's training skills, of the technologies that ultimately will help our patients and for fostering an environment where innovation can actually be nurtured. My experience at Texas Heart Institute has been absolutely fantastic. It's been the culmination of the ability to participate in clinical excellence, be able to participate in groundbreaking translational research and having amazing mentors that have been available to me throughout my four years of being here. We've really been on the forefront of cutting-edge technologies in collaboration with our partners over at Rice and UCLA. We've been able to develop novel pacing mechanisms, meeting unmet needs and also being able to develop carbon nanotubule fibers in the hopes of being able to reconstitute conduction. These chips are capable of harvesting radio frequency energy from distant sources and then reliably delivering enough energy to capture focal myocardium. When we arrange these chips in a network around the heart, we can use custom-tailored pacing programs to achieve re-synchronization in patients who were previously non-responders to traditional techniques. At the Texas Heart Institute, we've really been fortunate enough through our experiences as a fellow to kind of start with taking things from initial conception all the way through to design. And we've been able to do this in collaboration with many thought leaders, business leaders with our partners over at TMCX, Rice, and a bunch of other institutions as well. The Texas Medical Center is known for a lot of great research and certainly a lot of great clinical activity and probably nothing more so than in cardiology with great institutions like the Texas Heart here in town. We've got a lot of companies come through here working on polymeric valves or other kinds of devices, cardiac devices and implantables, and for them to be able to work with great clinicians, great fellows, co-develop and test those products pre-clinically and clinically. No better place in the country for cardiology companies to come and work. Being part of the Texas Medical Center complex, the largest medical center in the world, we now have the unique opportunity to have our fellows, our cardiology fellows participate in the TMC innovation incubator and cross-pollinate with the engineers and the business people in Houston and by providing new ideas and needs and in turn learning how to develop those ideas and how to navigate those ideas to fruition. In mind that we have eight million patient encounters a year here at the Texas Medical Center, we now have the unique ability to bring these patients together with the forefront of technology and use this opportunity to develop this technology to offer these patients the best, not only in terms of treatment but in terms of outcomes.